Skip to main content

Correction to: The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice

The Original Article was published on 04 January 2021

Correction to: Alzheimers Res Ther 13, 6 (2021)

https://doi.org/10.1186/s13195-020-00743-x

Following publication of the original article [1], the authors reported an error in Figure 5 and Supplementary Figure 9. In Figure 5, the same image was included, by mistake, in panels c and d. The corrected Figure 5 shows the correct image in panel c. Similarly, in Supplementary Figure 9, panels G and K show, by mistake, the same image. The corrected Supplementary Figure 9 shows the correct image in panel G, presented below as Fig. 1.

Fig. 1
figure1

Analysis of pre-synapse and post-synapse in the CA3 region. Brain sections were stained using anti-bassoon (ae) or anti-homer (gk) antibodies. Representative images are shown for a, g) wild-type mice treated with vehicle (WT-0), b, h) wild-type mice treated with 1.0 mg/Kg CLR01 (WT-1.0), c, i) P301S-tau mice treated with vehicle (Tg-0), d, j) P301S-tau mice treated with 0.3 mg/Kg CLR01 (Tg-0.3), and e, k) P301S-tau mice treated with 1.0 mg/Kg CLR01. The data were quantified as the number of puncta per unit area in the CA3 region for Bassoon (f) and Homer (l)

Fig. 5
figure2

CLR01 treatment reduces hyperphosphorylated tau in the hippocampus of P301S-tau mice. Brain sections from P301S-tau mice were stained with monoclonal antibody AT8 and visualized by immunofluorescence. a The typical crescent shape of the hippocampus was delineated by an operator blinded to treatment. bd Representative images of the hippocampus area of mice treated with 0 (a), 0.3 (b), or 1.0 (c) mg/kg per day CLR01. d The data were quantified as the percentage of AT8-positive area within the hippocampus area, as defined in panel a. The data are presented as mean ± SD. P values were calculated using a one-way ANOVA with post hoc Tukey test

Reference

  1. 1.

    Di J, Siddique I, Li Z, Malki G, Hornung S, Dutta S, et al. The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. Alzheimers Res Ther. 2021;13(1):6. https://doi.org/10.1186/s13195-020-00743-x.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gal Bitan.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Di, J., Siddique, I., Li, Z. et al. Correction to: The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. Alz Res Therapy 13, 88 (2021). https://doi.org/10.1186/s13195-021-00823-6

Download citation